Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Dicks Sporting Goods Inc (DKS) Price & Performance

ADMA Biologics IncTrade
Dicks Sporting Goods IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Dicks Sporting Goods Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Dicks Sporting Goods Inc trades at $206.29 (market cap $19.16B). The key difference: Dicks Sporting Goods Inc is far larger — about 8.8× ADMA Biologics Inc's market cap, and Dicks Sporting Goods Inc pays a 2.34% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMADKS
Market Cap
$2.18B$19.16B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$239.17
52-Week Low
$7.60$187.78
Enterprise Value
$2.25B$25.95B
Dividend Yield
2.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Dicks Sporting Goods Inc

DICK'S Sporting Goods (DKS) trades at $208.84, up 5.15% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals with support at $201 and resistance at $213. Fundamentally, the company maintains solid profitability with 20.9% ROE and 4.71% net margin, though cash flow trends show modest net outflows. Recent news highlights analyst upgrades and the upcoming Q2 earnings call on August 25th.

The investment outlook remains positive with 59% analyst buy ratings and a $263.22 consensus target representing 26% upside. Key risks include potential fiduciary duty investigations and competitive pressures in sporting goods retail. The company's consistent earnings beats and expanding women's sports investments provide catalysts, though investors should monitor cash flow sustainability and market volatility.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS